Transforming life for people living with Parkinson’s and other CNS disorders

Transforming life for people living with Parkinson’s and other CNS disorders

LATEST PRESS RELEASES
OCTOBER 30, 2024 / REGULATORY

IRLAB publishes interim report for the period January – September 2024

Gothenburg, Sweden, October 30, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January-September 2024, has been published.

Read More >

Watch IRLAB’s
Capital Markets Day 2023!

IRLAB A
13.65
SEK
TODAY
-1.09 %
TODAY SEK
-0.15 SEK
10:18:31
2024-11-12
More share info >

ISP – The proprietary technology platform

IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

IRLAB’s clinical phase II candidates

Mesdopetam (IRL790)

In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.  

Pirepemat (IRL752)

In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.

LATEST PRESENTATION
OCTOBER 25, 2024

Presentation at Redeye’s Theme Event Neurology

Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.

Read More >